Immunosuppression Drug Therapy in Lung Transplantation for Cystic Fibrosis. 
Cystic fibrosis (CF) is a common indication for lung transplantation (LTx) in children and adults with severe and irreversible lung disease.  In the setting of LTx in the CF population, immunosuppressive medications are used to prevent allograft rejection despite the majority of these patients being chronically infected with numerous, and often antibiotic-resistant, pathogens.  There is limited evidence for the optimal post-LTx immunosuppression regimen in patients with CF, particularly in children.  This article provides a review of immunosuppression regimens in the pediatric and adult CF post-LTx population, investigating drug dosing and monitoring, and medication combinations.  Currently used immunosuppressive medications and related systemic adverse effects are reviewed.  With limitations of data in the pediatric population, future research should address immunosuppression in these children to help guide pediatric drug management as a means to optimize clinical outcomes after LTx.